• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

波兰、捷克共和国、匈牙利、罗马尼亚和保加利亚的卫生技术评估。

Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria.

机构信息

Department of Health Economics, Corvinus University of Budapest, Fővám tér 8., 1093, Budapest, Hungary,

出版信息

Eur J Health Econ. 2014 May;15 Suppl 1:S13-25. doi: 10.1007/s10198-014-0590-8. Epub 2014 May 16.

DOI:10.1007/s10198-014-0590-8
PMID:24832832
Abstract

This paper describes and discusses the development and use of health technology assessment (HTA) in five Central and Eastern European countries (CEE): Poland, the Czech Republic, Hungary, Romania and Bulgaria. It provides a general snapshot of HTA policies in the selected CEE countries to date by focusing on country case-studies based on document analysis and expert opinion. It offers an overview of similarities and differences between the individual CEE countries and discusses in detail the role of HTA by assessing its formalization and institutionalization, standardization of methodology, the use of HTA in practice and the degree of professionalization of HTA in the region. It finds that HTA has been to some extent implemented in all five countries studied, with methodologies in accordance with international standards, but that challenges remain when it comes to the role of HTA in health care decision-making as well as to human resource capacities of the countries. This paper suggests that coming years will show whether CEE countries develop adequate national analytical capacity to assess and appraise technologies in the context of local need and affordability, instead of using HTA as a mere administrative procedure to fulfill (inter)national requirements. Finally, suggestions are provided to strengthen HTA in CEE countries through cooperation, mutual learning, a common accreditation of HTA bodies and increased network building among CEE HTA experts.

摘要

本文描述并讨论了在五个中东欧国家(CEE):波兰、捷克共和国、匈牙利、罗马尼亚和保加利亚开发和使用健康技术评估(HTA)的情况。本文通过基于文献分析和专家意见的案例研究,聚焦于选定的 CEE 国家,提供了迄今为止 CEE 国家 HTA 政策的总体概况。本文概述了 CEE 国家之间的相似点和不同点,并详细讨论了 HTA 的作用,评估了其正式化和制度化、方法标准化、在实践中的使用以及该地区 HTA 的专业化程度。研究发现,HTA 在所有五个研究国家都在一定程度上得到了实施,其方法符合国际标准,但在 HTA 在医疗保健决策中的作用以及各国人力资源能力方面仍存在挑战。本文认为,未来几年将表明 CEE 国家是否能够发展出足够的国家分析能力,以在当地需求和可负担性的背景下评估和评估技术,而不是将 HTA 仅仅作为一种满足(国际)要求的行政程序。最后,本文提出了通过合作、相互学习、共同认证 HTA 机构以及加强 CEE HTA 专家之间的网络建设来加强 CEE 国家 HTA 的建议。

相似文献

1
Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria.波兰、捷克共和国、匈牙利、罗马尼亚和保加利亚的卫生技术评估。
Eur J Health Econ. 2014 May;15 Suppl 1:S13-25. doi: 10.1007/s10198-014-0590-8. Epub 2014 May 16.
2
Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries.卫生技术评估在实施欧盟透明度指令过程中的作用:来自中东欧国家的相关经验。
Expert Rev Pharmacoecon Outcomes Res. 2012 Jun;12(3):283-7. doi: 10.1586/erp.12.12.
3
Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.中东欧国家的药品监管:当前综述
Front Pharmacol. 2017 Dec 18;8:892. doi: 10.3389/fphar.2017.00892. eCollection 2017.
4
HTA Implementation Roadmap in Central and Eastern European Countries.中东欧国家的卫生技术评估实施路线图。
Health Econ. 2016 Feb;25 Suppl 1(Suppl Suppl 1):179-92. doi: 10.1002/hec.3298. Epub 2016 Jan 14.
5
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.中东欧的肿瘤孤儿药的卫生技术评估和报销政策。
Orphanet J Rare Dis. 2020 Oct 8;15(1):277. doi: 10.1186/s13023-020-01556-9.
6
Recommendations for patient involvement in health technology assessment in Central and Eastern European countries.在中东欧国家,关于患者参与卫生技术评估的建议。
Front Public Health. 2023 Jul 3;11:1176200. doi: 10.3389/fpubh.2023.1176200. eCollection 2023.
7
Eastern Europe: pronatalist policies and private behavior.东欧:鼓励生育政策与个人行为
Popul Bull. 1982 Feb;36(6):1-49.
8
OVERVIEW ON THE CURRENT IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN THE HEALTHCARE SYSTEM IN HUNGARY.匈牙利医疗卫生系统中卫生技术评估的现行实施概况。
Int J Technol Assess Health Care. 2017 Jan;33(3):333-338. doi: 10.1017/S0266462317000071. Epub 2017 Apr 24.
9
Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment.克服人工智能驱动的证据在健康技术评估中应用障碍的建议。
Front Public Health. 2023 Apr 26;11:1088121. doi: 10.3389/fpubh.2023.1088121. eCollection 2023.
10
Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.医疗设备在中东欧的 HTA 走向何方?解决方法学挑战的建议。
Front Public Health. 2021 Jan 8;8:612410. doi: 10.3389/fpubh.2020.612410. eCollection 2020.

引用本文的文献

1
A Multidisciplinary and Longitudinal Framework for Enhancing Innovation Efficiency in Healthcare Systems.一个用于提高医疗保健系统创新效率的多学科纵向框架。
J Multidiscip Healthc. 2025 Apr 8;18:1969-1984. doi: 10.2147/JMDH.S497613. eCollection 2025.
2
Overcoming Barriers in Hospital-Based Health Technology Assessment (HB-HTA): International Expert Panel Consensus.克服医院健康技术评估(HB-HTA)中的障碍:国际专家小组共识
Healthcare (Basel). 2024 Apr 25;12(9):889. doi: 10.3390/healthcare12090889.
3
Population norms for the EQ-5D-3L and EQ-5D-5L in Romania.

本文引用的文献

1
Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary.新型医疗技术报销中的多标准决策分析:来自匈牙利的实际经验。
Value Health. 2014 Jun;17(4):487-9. doi: 10.1016/j.jval.2014.01.011. Epub 2014 Apr 29.
2
Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.2005-2012 年支持 FDA 批准新型治疗药物的临床试验证据。
JAMA. 2014;311(4):368-77. doi: 10.1001/jama.2013.282034.
3
Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems.
罗马尼亚人群的 EQ-5D-3L 和 EQ-5D-5L 量表常模。
Health Qual Life Outcomes. 2023 Jul 29;21(1):80. doi: 10.1186/s12955-023-02144-8.
4
A SWOT analysis of the complex interdependencies of the Maltese reimbursement processes.对马耳他报销流程复杂相互依存关系的SWOT分析。
Health Policy Open. 2023 Apr 10;4:100095. doi: 10.1016/j.hpopen.2023.100095. eCollection 2023 Dec.
5
Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment.克服人工智能驱动的证据在健康技术评估中应用障碍的建议。
Front Public Health. 2023 Apr 26;11:1088121. doi: 10.3389/fpubh.2023.1088121. eCollection 2023.
6
Using the Dynamic SWOT Analysis to Assess Options for Implementing the HB-HTA Model.运用动态 SWOT 分析评估实施 HB-HTA 模型的方案。
Int J Environ Res Public Health. 2022 Jun 14;19(12):7281. doi: 10.3390/ijerph19127281.
7
Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries.卫生技术评估系统的异同及其对覆盖决策的影响:来自32个国家的证据
Pharmacoecon Open. 2022 May;6(3):315-328. doi: 10.1007/s41669-021-00311-5. Epub 2021 Nov 29.
8
Quality of life in people living with HIV in Romania and Spain.罗马尼亚和西班牙艾滋病毒感染者的生活质量。
BMC Infect Dis. 2021 Sep 13;21(Suppl 2):898. doi: 10.1186/s12879-021-06567-w.
9
A Divide between the Western European and the Central and Eastern European Countries in the Peripheral Vascular Field: A Narrative Review of the Literature.西欧与中东欧国家在周围血管领域的差异:文献综述
J Clin Med. 2021 Aug 12;10(16):3553. doi: 10.3390/jcm10163553.
10
Recommendations for the Implementation of Hospital Based HTA in Poland: Lessons Learned From International Experience.波兰医院层面卫生技术评估实施建议:国际经验教训
Front Pharmacol. 2021 May 13;11:594644. doi: 10.3389/fphar.2020.594644. eCollection 2020.
欧洲国家卫生技术评估系统非排名分类与比较的原型开发。
Health Policy. 2013 Dec;113(3):305-12. doi: 10.1016/j.healthpol.2013.09.007. Epub 2013 Sep 25.
4
Applying rapid 'de-facto' HTA in resource-limited settings: experience from Romania.在资源有限的情况下应用快速“事实上”的卫生技术评估:来自罗马尼亚的经验。
Health Policy. 2013 Oct;112(3):202-8. doi: 10.1016/j.healthpol.2013.07.019. Epub 2013 Aug 14.
5
Health technology assessment in Poland and Scotland: comparison of process and decisions.波兰和苏格兰的卫生技术评估:过程和决策的比较。
Int J Technol Assess Health Care. 2012 Jan;28(1):70-6. doi: 10.1017/S0266462311000699.
6
A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland.对 2007 年至 2009 年间发布的药物治疗卫生技术评估(HTA)建议进行综述及其对波兰决策过程的影响。
Health Policy. 2011 Oct;102(2-3):145-51. doi: 10.1016/j.healthpol.2011.05.001.
7
Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions.在医疗保健决策中使用每获得一个质量调整生命年的成本阈值。
Int J Technol Assess Health Care. 2011 Jan;27(1):71-6. doi: 10.1017/S0266462310001194. Epub 2011 Jan 25.
8
The NICE cost-effectiveness threshold: what it is and what that means.英国国家卫生与临床优化研究所(NICE)的成本效益阈值:是什么以及意味着什么。
Pharmacoeconomics. 2008;26(9):733-44. doi: 10.2165/00019053-200826090-00004.
9
Issues for countries considering introducing the "fourth hurdle": the case of Hungary.考虑引入“第四道门槛”的国家所面临的问题:以匈牙利为例。
Int J Technol Assess Health Care. 2004 Summer;20(3):337-41. doi: 10.1017/s0266462304001151.